NSCLC HARBORING NRG1 FUSION

Clinical trials for NSCLC HARBORING NRG1 FUSION explained in plain language.

Never miss a new study

Get alerted when new NSCLC HARBORING NRG1 FUSION trials appear

Sign up with your email to follow new studies for NSCLC HARBORING NRG1 FUSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Targeted drug combo tested for Tough-to-Treat cancers

Disease control Terminated

This study tested a drug called zenocutuzumab, combined with other cancer medications, for people with two specific advanced cancers. It aimed to see if the combinations could help control tumors in patients with a certain genetic change (NRG1+) in their lung cancer or in men who…

Matched conditions: NSCLC HARBORING NRG1 FUSION

Phase: PHASE2 • Sponsor: Merus B.V. • Aim: Disease control

Last updated Mar 18, 2026 14:41 UTC

NSCLC HARBORING NRG1 FUSION

Get alerted when new NSCLC HARBORING NRG1 FUSION trials appear

Targeted drug combo tested for Tough-to-Treat cancers